Literature DB >> 2445886

The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.

T Fujita1, T Inoue, K Ogawa, K Iida, N Tamura.   

Abstract

DAF is a 70,000-Mr membrane protein that inhibits the amplification of the complement cascade on the cell surface, and protects cells from damage by complement. The precise mechanism of action of DAF is not entirely clear. Purified DAF was incorporated into the membrane of EAC4b cells. EAC4b2 and EDAF AC4b2 cells were prepared with radiolabeled C2. The same amount of labeled C2 bound to both cells, showing that DAF does not prevent the binding of C2 zymogen to C4b. After adding Cl, the radioactivity of bound C2 dissociated more rapidly from EDAF AC4b cells than from EAC4b cells. In EAC4b cells, bound C2 was converted to C2a, which gradually dissociated into the supernatants. In the DAF-treated cells, on the other hand, a large amount of C2a rapidly appeared in the supernatants and only a small amount of C2a remained on the cells. In a similar experiment using EhuAC4b, DAF on human erythrocyte membrane also dissociated the C2a from the cells. These results were confirmed by hemolytic assay and the accelerated decay of C2a caused the rapid depletion of C2 from the fluid phase. In addition, we found that DAF functions on the alternative pathway C3 convertase, C3bBb in the same manner. Thus, DAF, which associates with C4b and C3b in the membrane, acts on C2a and Bb, but not on intact C2 and B, and dissociates them rapidly from the binding sites, thereby preventing the assembly of the classical and alternative pathways C3 convertases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445886      PMCID: PMC2189641          DOI: 10.1084/jem.166.5.1221

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Isolation and properties of a glycine-rich beta-glycoprotein of human serum.

Authors:  T Boenisch; C A Alper
Journal:  Biochim Biophys Acta       Date:  1970-12-22

3.  Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action.

Authors:  E M Hoffmann
Journal:  Immunochemistry       Date:  1969-05

4.  Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata.

Authors:  E M Hoffman
Journal:  Immunochemistry       Date:  1969-05

5.  Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b.

Authors:  S Nagasawa; R M Stroud
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

6.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

7.  Purification and structural analysis of the fourth component of human complement.

Authors:  C Bolotin; S Morris; B Tack; J Prahl
Journal:  Biochemistry       Date:  1977-05-03       Impact factor: 3.162

8.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

9.  The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase.

Authors:  M J Polley; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-09-01       Impact factor: 14.307

10.  Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.

Authors:  M E Medof; D M Lublin; V M Holers; D J Ayers; R R Getty; J F Leykam; J P Atkinson; M L Tykocinski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

View more
  47 in total

1.  CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.

Authors:  Imre Farkas; Lajos Baranyi; Yasushige Ishikawa; Noriko Okada; Csaba Bohata; Denes Budai; Atsuo Fukuda; Masaki Imai; Hidechika Okada
Journal:  J Physiol       Date:  2002-03-01       Impact factor: 5.182

2.  Expression and localization of proteins of the complement system in human skin.

Authors:  N Dovezenski; R Billetta; I Gigli
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

3.  Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants.

Authors:  D M Lublin; E S Thompson; A M Green; C Levene; M J Telen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  Intercellular transfer of a glycosylphosphatidylinositol (GPI)-linked protein: release and uptake of CD4-GPI from recombinant adeno-associated virus-transduced HeLa cells.

Authors:  S M Anderson; G Yu; M Giattina; J L Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

5.  NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

Authors:  Siao-Yi Wang; Emilian Racila; Ronald P Taylor; George J Weiner
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

6.  A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation.

Authors:  Kathryn R Girard-Pierce; Sean R Stowell; Nicole H Smith; C Maridith Arthur; Harold C Sullivan; Jeanne E Hendrickson; James C Zimring
Journal:  Blood       Date:  2013-07-22       Impact factor: 22.113

7.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

8.  The intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injury.

Authors:  Masashi Sakuma; Toshifumi Morooka; Yunmei Wang; Can Shi; Kevin Croce; Huiyun Gao; Michael Strainic; M Edward Medof; Daniel I Simon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-03-18       Impact factor: 8.311

9.  Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.

Authors:  X Sun; C D Funk; C Deng; A Sahu; J D Lambris; W C Song
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

10.  Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.

Authors:  Jennifer White; Petra Lukacik; Dirk Esser; Michael Steward; Naomi Giddings; Jeremy R Bright; Sarah J Fritchley; B Paul Morgan; Susan M Lea; Geoffrey P Smith; Richard A G Smith
Journal:  Protein Sci       Date:  2004-09       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.